Accentia Biopharmaceuticals (ABPI) Agrees to $8.5M Private Placement to Fund SinuNase(TM) and Revimmune(TM) Strategies
More News related to ABPI
- Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
- Accentia Biopharmaceuticals (ABPI) Agrees to $8.5M Private Placement to Fund SinuNase(TM) and Revimmune(TM) Strategies
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Announces SinuNase Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant
- Pre-Open Movers 4/17: FUQI Intl (FUQI) Higher on Raised Guidance, Nokia (NOK) Lower on Results/Outlook
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) today announced that it has entered into definitive agreements for an $8.5 million private placement offering of Secured Convertible Debentures and common stock purchase Warrants to existing institutional investors. Rodman & Renshaw acted as the exclusive placement agent.
Accentia intends to use the proceeds to support development, regulatory and partnering strategies for SinuNase(TM) and Revimmune(TM) and support general operations.
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology.
Related Categories
Corporate NewsEquity Offerings
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
